A/Prof Marc Russo and colleagues recently conducted a systematic review and meta-analysis, published in Pain Physician, examining the use of cannabinoids in the management of fibromyalgia-related pain.
The analysis brought together 12 clinical studies involving more than 1,200 patients, including both randomised controlled trials and observational research.
Overall, the findings showed that cannabinoids were associated with a statistically significant reduction in pain intensity. Improvements were also seen in sleep quality, anxiety, depression, and overall quality of life.
However, the evidence was of low quality and showed significant variability between studies, with limited data from randomised controlled trials. Because of this, the findings should be interpreted with caution.
Reported side effects included dizziness, dry mouth, and drowsiness, while serious adverse effects were uncommon.
In summary, the research suggests cannabinoids may offer pain relief for some patients with fibromyalgia, with potential benefits for sleep and mood. Further high-quality studies are needed to better understand their role in long-term management.
Read the full study here for more detail.